Diane M. Harper

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

H. Kitchener, M. Lehtinen, X. Castellsagué, 2012, The Lancet. Oncology.